Ignite Creation Date:
2024-05-06 @ 8:57 AM
Last Modification Date:
2024-10-26 @ 12:07 PM
Study NCT ID:
NCT02866903
Status:
UNKNOWN
Last Update Posted:
2017-09-21
First Post:
2016-08-04
Brief Title:
Safety of Intraperitoneal IP OXAliplatin OXA in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
IPOXA Phase III Dose Escalation Trial Aiming to Evaluate the Safety of Intraperitoneal IP OXAliplatin OXA in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis of Colorectal Origin and Uncertain Resectability
Status:
UNKNOWN
Status Verified Date:
2017-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IPOXA
Brief Summary:
Peritoneal carcinosis PC corresponds to a locoregional extension into the peritoneum of rare primary peritoneal cancers or more frequently distant extension of digestive cancers colorectal or gastric or gynecological ovarian fallopian tube or endometrial PC can be considered as a distinct oncological entity as its genesis natural history and response to systematic treatments differ to those of other metastases The development of PC observed in 25-35 of colorectal cancers is generally considered as a unfavorable event in the course of the disease The prognosis is defined by the possibility of complete resection possibly after neoadjuvant treatment The benefit provided by the combination of cytoreductive surgery and heated intraperitoneal chemotherapy HIPEC with respect to systemic chemotherapy in patients with PC of colorectal origin has been demonstrated based on overall survival in several randomized trials among which one evaluated oxaliplatin The evaluation of the clinical benefit-risk related to the repeated administration of non-hyperthermic intraperitoneal chemotherapy as has been validated in ovarian cancer in patients with PC of colorectal origin is already being investigated by several international teams
The FOLFOXIRI bevacizumab every 2 weeks is a modern therapeutic option in patients with this disease The intraperitoneal rather than intravenous IV administration of oxaliplatin in this combination could increase the response of peritoneal lesions known to be relatively insensitive to IV chemotherapy
The FOLFOXIRI bevacizumab every 2 weeks is a modern therapeutic option in patients with this disease The intraperitoneal rather than intravenous IV administration of oxaliplatin in this combination could increase the response of peritoneal lesions known to be relatively insensitive to IV chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None